FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002486813> ?p ?o ?g. }

• W2002486813 endingPage "996" @default.
• W2002486813 startingPage "987" @default.
• W2002486813 abstract "For metastatic bladder cancer patients, systemic cisplatin (CDDP)-based combination chemotherapy is the first-line choice of treatment. Although up to 70% of advanced bladder cancer patients initially show good tumor response to this form of combination chemotherapy, over 90% of good responders relapse and eventually die of the disease. According to the cancer stem cell theory, this phenomenon is attributable to the re-growth of bladder cancer-initiating cells (BCICs) that have survived chemotherapy. In this study, the authors have isolated BCICs from cultured human bladder cancer cells to analyze their sensitivity to CDDP and to investigate whether heat-shock protein 90 (Hsp90) inhibitors potentiate the cytotoxicity of CDDP on BCICs. First, the authors have confirmed that a CD44+ subpopulation of 5637 cells met the requirements to be considered tumor-initiating cells. These BCICs were more resistant to CDDP and exhibited more activity in the Akt and ERK oncogenic signaling pathways when compared with their CD44− counterparts. The Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), which simultaneously inactivated both Akt and ERK signaling at noncytocidal concentrations, synergistically potentiated the cytotoxicity of CDDP against BCICs by enhancing CDDP-induced apoptosis in vitro. The potentiating effect of 17-DMAG was more effective than a combination of the two inhibitors specific for the Akt and ERK pathways. Finally, the authors have confirmed that, though human BCIC xenografts exhibited resistance to a single administration of CDDP and the Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), 17-AAG sensitized them to CDDP in a mouse model. These data encourage clinical trials of Hsp90 inhibitors as they may improve therapeutic outcomes of CDDP-based combination chemotherapy against advanced bladder cancer." @default.
• W2002486813 created "2016-06-24" @default.
• W2002486813 creator A5015291340 @default.
• W2002486813 creator A5018089497 @default.
• W2002486813 creator A5031050928 @default.
• W2002486813 creator A5060240988 @default.
• W2002486813 creator A5064683515 @default.
• W2002486813 creator A5088037725 @default.
• W2002486813 creator A5089503656 @default.
• W2002486813 date "2011-11-10" @default.
• W2002486813 modified "2023-09-26" @default.
• W2002486813 title "Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells" @default.
• W2002486813 cites W102593176 @default.
• W2002486813 cites W1552614585 @default.
• W2002486813 cites W1596376889 @default.
• W2002486813 cites W1820014750 @default.
• W2002486813 cites W1975779037 @default.
• W2002486813 cites W1976203623 @default.
• W2002486813 cites W1976431370 @default.
• W2002486813 cites W1980708527 @default.
• W2002486813 cites W1992514491 @default.
• W2002486813 cites W1997280228 @default.
• W2002486813 cites W2001544973 @default.
• W2002486813 cites W2005266975 @default.
• W2002486813 cites W2009857031 @default.
• W2002486813 cites W2009899654 @default.
• W2002486813 cites W2011810742 @default.
• W2002486813 cites W2014573616 @default.
• W2002486813 cites W2019264784 @default.
• W2002486813 cites W2022531767 @default.
• W2002486813 cites W2023427658 @default.
• W2002486813 cites W2023964913 @default.
• W2002486813 cites W2024520801 @default.
• W2002486813 cites W2040272587 @default.
• W2002486813 cites W2051055358 @default.
• W2002486813 cites W2058763255 @default.
• W2002486813 cites W2060551076 @default.
• W2002486813 cites W2062069198 @default.
• W2002486813 cites W2064247262 @default.
• W2002486813 cites W2077007440 @default.
• W2002486813 cites W2077576218 @default.
• W2002486813 cites W2077945404 @default.
• W2002486813 cites W2081447858 @default.
• W2002486813 cites W2082390299 @default.
• W2002486813 cites W2089753996 @default.
• W2002486813 cites W2090982381 @default.
• W2002486813 cites W2114788766 @default.
• W2002486813 cites W2120325329 @default.
• W2002486813 cites W2122225869 @default.
• W2002486813 cites W2135231064 @default.
• W2002486813 cites W2145597335 @default.
• W2002486813 cites W2157158866 @default.
• W2002486813 cites W2158734599 @default.
• W2002486813 cites W2159640574 @default.
• W2002486813 cites W2160284804 @default.
• W2002486813 cites W2171459779 @default.
• W2002486813 cites W2171648963 @default.
• W2002486813 doi "https://doi.org/10.1002/ijc.26475" @default.
• W2002486813 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7447157" @default.
• W2002486813 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21964864" @default.
• W2002486813 hasPublicationYear "2011" @default.
• W2002486813 type Work @default.
• W2002486813 sameAs 2002486813 @default.
• W2002486813 citedByCount "62" @default.
• W2002486813 countsByYear W20024868132012 @default.
• W2002486813 countsByYear W20024868132013 @default.
• W2002486813 countsByYear W20024868132014 @default.
• W2002486813 countsByYear W20024868132015 @default.
• W2002486813 countsByYear W20024868132016 @default.
• W2002486813 countsByYear W20024868132017 @default.
• W2002486813 countsByYear W20024868132018 @default.
• W2002486813 countsByYear W20024868132019 @default.
• W2002486813 countsByYear W20024868132020 @default.
• W2002486813 countsByYear W20024868132021 @default.
• W2002486813 countsByYear W20024868132022 @default.
• W2002486813 countsByYear W20024868132023 @default.
• W2002486813 crossrefType "journal-article" @default.
• W2002486813 hasAuthorship W2002486813A5015291340 @default.
• W2002486813 hasAuthorship W2002486813A5018089497 @default.
• W2002486813 hasAuthorship W2002486813A5031050928 @default.
• W2002486813 hasAuthorship W2002486813A5060240988 @default.
• W2002486813 hasAuthorship W2002486813A5064683515 @default.
• W2002486813 hasAuthorship W2002486813A5088037725 @default.
• W2002486813 hasAuthorship W2002486813A5089503656 @default.
• W2002486813 hasBestOaLocation W20024868132 @default.
• W2002486813 hasConcept C104317684 @default.
• W2002486813 hasConcept C109316439 @default.
• W2002486813 hasConcept C121608353 @default.
• W2002486813 hasConcept C126322002 @default.
• W2002486813 hasConcept C1491633281 @default.
• W2002486813 hasConcept C190283241 @default.
• W2002486813 hasConcept C202751555 @default.
• W2002486813 hasConcept C205260736 @default.
• W2002486813 hasConcept C2775932338 @default.
• W2002486813 hasConcept C2776694085 @default.
• W2002486813 hasConcept C2777560012 @default.
• W2002486813 hasConcept C2778239845 @default.
• W2002486813 hasConcept C2780352672 @default.

• next